Skip to content

Current pharmaceutical design

ISSN 1873-4286

3 papers in the library · 3 citations · publishing 2002-2025

Papers

Esketamine Regulates Mitophagy through ULK1/FUNDC1 Signaling Pathway to Improve LPS-induced Acute Respiratory Distress Syndrome.

Current pharmaceutical design February 28, 2025 Mei Ding, Ping Pei, Weihua Liu et al. 3 citations

In a mouse model of acute respiratory distress syndrome (ARDS) induced by inhaled lipopolysaccharide, esketamine treatment reduced lung damage, improved pulmonary vascular permeability, and suppressed inflammation, oxidative stress, and apoptosis. The drug activated mitophagy through the ULK1/FUNDC1 signaling pathway. These results suggest esketamine has therapeutic potential for ARDS.

Resting state abnormalities in psychosis compared to acute cannabinoids and opioids challenges: a systematic review of functional imaging studies.

Current pharmaceutical design January 1, 2012 Niklaus Denier, Marc Walter, Kerstin Bendfeldt et al.

A systematic review compared resting-state cerebral blood flow patterns in first-episode psychosis (FEP), acute cannabinoid intoxication, and acute opioid intoxication. The evidence was highly conflicting within each condition, but some consistent findings emerged: both positive symptoms of FEP and depersonalization after cannabis administration were linked to increased activity in the anterior cingulate cortex, a key region of the default mode network. The review included 22 studies with 279 FEP participants or controls, 315 participants receiving cannabinoids, and 113 receiving opioids.

Analysis of overall gene expression induced by amphetamine and phencyclidine: novel targets for the treatment of drug psychosis and schizophrenia.

Current pharmaceutical design January 1, 2002 Chihiro Ito

A review suggests that amphetamine and phencyclidine alter the expression of genes related to neurotransmitter systems (dopamine, glutamic acid), transcription factors, cell proliferation, apoptosis, cell adhesion, and synapses in animal models. These changes in gene expression may help identify candidate genes for drug psychosis or schizophrenia and lead to the development of novel antipsychotics.